

Please refer to Announcement Number 794 when requesting information and submitting an application.

This and other CDC announcements are also available through the CDC homepage on the Internet. The address for the CDC homepage is <http://www.cdc.gov>.

CDC will not send application kits by facsimile or express mail.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report, Stock No. 017-001-00473-1) referenced in the Introduction through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone: 202-512-1800.

Dated: May 20, 1997.

**Joseph R. Carter,**

*Acting Associate Director for Management and Operations Centers for Disease Control and Prevention (CDC).*

[FR Doc. 97-13744 Filed 5-23-97; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreement for Research Projects for Persons With Disabilities and Prevention of Secondary Conditions, Program Announcement 731, Part 2: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreement for Research Projects for Persons with Disabilities and Prevention of Secondary Conditions, Program Announcement 731, Part 2.

*Time and Date:* 8:30 a.m.-2:00 p.m., June 13, 1997

*Place:* Koger Office Park, Vanderbilt Building, Room 1004-A, 2939 Flowers Road, South, Atlanta, Georgia 30341.

*Status:* Closed.

*Matters to be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 731, Part 2.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and

the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

*Contact Person For More Information:* James S. Belloni, Associate Director, State and Community Activities, National Center for Injury Prevention and Control, CDC, M/S K02, 4770 Buford Highway, NE, Atlanta, Georgia 30341-3724, telephone 770/488-4538.

Dated: May 14, 1997.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 97-13747 Filed 5-23-97; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### The National Center for HIV, STD, and TB Prevention (NCHSTP) of the Centers for Disease Control and Prevention (CDC); Announces the Following Meeting

*Name:* Consultation on Guidelines for HIV Partner Notification Conducted in Disease Control Efforts by Public Health Programs in the United States.

*Times and Dates:* 8:30 a.m.-5 p.m., June 17, 1997, 8:30 a.m.-12 p.m., June 18, 1997.

*Place:* Wyndham Gardens Hotel, 125 10th Street, NE (Midtown), Atlanta, Georgia, 30309, telephone 404/873-4800, fax 404/870-1530.

*Status:* Open to the public for participation, comment, and observation, limited only by the space available. The meeting room accommodates approximately 25 people.

*Purpose:* To invite comment from representatives of public health agencies and the public on revising the existing HIV partner notification guidelines. Currently CDC requires all health department recipients of HIV prevention funding to "establish standards and implement procedures for partner notification consistent with State/local needs, priorities, and resource availability."

*Matters to be Discussed:* Agenda items will focus on discussion of HIV partner notification guidelines that will accompany the announcement for FY 98 HIV Prevention Cooperative Agreements. Discussion will also include directions of supplemental HIV partner notification guidelines for the purpose of disease control in the United States concerning HIV and STD.

Agenda items are subject to change as priorities dictate.

**CONTACT PERSON FOR MORE INFORMATION:** Jill Leslie, Division of HIV/AIDS Prevention, NCHSTP, CDC, M/S E40, 1600 Clifton Road, NE, Atlanta, Georgia 30303, telephone 404/639-2918.

Dated: May 19, 1997.

**John C. Burckhardt,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 97-13746 Filed 5-23-97; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 97M-0203]

#### Bard Vascular Systems Division, C. R. Bard, Inc.; Premarket Approval of Bard® Albumin Coated DeBakey® Vasculour®-II Vascular Prosthesis

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application by C. R. Bard, Inc., Billerica, MA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of Bard® Albumin Coated DeBakey® Vasculour®-II Vascular Prosthesis. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter on October 21, 1994, of the approval of the application.

**DATES:** Petitions for administrative review by June 26, 1997.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review, to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Dorothy B. Abel, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8262.

**SUPPLEMENTARY INFORMATION:** On January 14, 1993, C. R. Bard, Inc., Billerica, MA 01821, submitted to CDRH an application for premarket approval of Bard® Albumin Coated DeBakey® Vasculour®-II Vascular Prosthesis. The device is a vascular graft prosthesis and is indicated for replacement or bypass procedures in aneurysmal and occlusive diseases of the abdominal arteries.